In 2018, three domestic tinies will be listed one after another. Who will become the fourth approved domestic tinies in the year?

A few days ago, fujiquitinib, a class 1 new drug developed by Hutchison Whampoa in 13 years, was officially approved for the market This is the third domestic Tinian drug approved this year The first two are androtinib of Zhengda Tianqing and pyrrolotinib of Hengrui Among them, since its listing in June, androtini has a strong momentum, with the first day's delivery volume reaching 130 million yuan, and the sales volume in the first year of listing is expected to hit 800 million yuan At the same time, pyrrolidine and furaquinidine are also highly expected Besides these, which will be the next heavyweight domestic TiNi? There are 5 TiNi drugs on the market, namely tyrosine kinase inhibitors (PTKs), which are small molecule protein kinase inhibitors and can block one or more protein kinases At present, most of them are antineoplastic drugs Up to now, there have been 5 independently developed TiNi drugs on the market in China, all of which are class 1 new drugs, namely, exetinib, apatinib, enrotinib, pyrrolidine and furaquinidine Among them, the original research companies of apatini and arrotini are Nanjing edcheng (the data comes from the official websites of various companies) it is worth mentioning that, as the first domestic Tinian drug to be listed on the market, the performance of exetinib is very eye-catching In 2017, the sales reached 1.026 billion yuan, breaking the 1 billion mark Apatini's sales volume in 2017 is estimated to be more than 1 billion yuan, and in 2018, the sales volume of arotini, which just went public, is expected to reach 800 million yuan Ivetinib is very likely to become the next approved Tinian drug Although some insiders thought that the Tinian drug had been broken a few years ago, the author thinks that the Tinian drug has great potential in the next few years, so which will be the next heavyweight Tinian drug on the market? At present, there are 12 TiNi drugs independently developed in China Among them, ivetinib maleate, the first third generation EGFR inhibitor in China, has made the fastest progress in research and development in Zhejiang Eisen pharmaceutical industry Its production report in August 2018 has been given priority review, and it is likely to become the next TiNi drug to be listed this year In addition, wallitini and nshatini are worthy of attention Ensatinib of Beida pharmaceutical, as the second generation of ALK inhibitor, has better efficacy than the first generation of clozatinib, and is expected to be marketed in 2019-2021 Waritinib is a highly selective oral small molecule c-met kinase inhibitor jointly developed by Hutchison Whampoa and AstraZeneca, which can effectively inhibit tumor growth, especially for the amplification of c-met gene or the overexpression of c-met protein The abnormal tumor has a significant inhibitory effect At present, the global development of voritinib has covered a variety of solid tumors with abnormal c-Met, including non-small cell lung cancer, renal cancer, gastric cancer and colorectal cancer, etc., which are about to enter the key research in multiple indications It can be predicted that once approved, voritinib will become another heavyweight drug approved by Hutchison Whampoa after furquitinib